4'- (4,4- difluoro- 5- (2- oxo- 2- (4- piperidinopiperidino)ethylidene)- 2,3,4,5- tetrahydro- 1H- 1- benzoazepine- 1- carbonyl)- 2- methyl- 3- furanilide

a vasopressin V(1A) receptor antagonist; structure in first source

Also Known As:

(Z)-4'-(4,4-difluoro-5-(2-oxo-2-(4-piperidinopiperidino)ethylidene)-2,3,4,5-tetrahydro-1H-1-benzoazepine-1-carbonyl)-2-methyl-3-furanilide hemifumarate; YM 218; YM-218; YM218

Networked: 4 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Piperidines: 17
    - 4'-(4,4-difluoro-5-(2-oxo-2-(4-piperidinopiperidino)ethylidene)-2,3,4,5-tetrahydro-1H-1-benzoazepine-1-carbonyl)-2-methyl-3-furanilide: 4
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzazepines: 5
      - 4'-(4,4-difluoro-5-(2-oxo-2-(4-piperidinopiperidino)ethylidene)-2,3,4,5-tetrahydro-1H-1-benzoazepine-1-carbonyl)-2-methyl-3-furanilide: 4

Experts

1.	Shibasaki, Masayuki: 3 articles (06/2007 - 01/2006)
2.	Suzuki, Takeshi: 3 articles (06/2007 - 01/2006)
3.	Tahara, Atsuo: 3 articles (06/2007 - 01/2006)
4.	Tomura, Yuichi: 3 articles (06/2007 - 01/2006)
5.	Tsukada, Junko: 3 articles (06/2007 - 01/2006)
6.	Yatsu, Takeyuki: 3 articles (06/2007 - 01/2006)
7.	Momose, Kazuhiro: 2 articles (05/2006 - 01/2006)
8.	Henning, Robert H: 1 article (12/2006)
9.	Kluppel, Alex C A: 1 article (12/2006)
10.	Tahara, Atsua: 1 article (12/2006)

Related Diseases

1.	Hyperplasia 06/01/2007 - "YM218 potently prevented AVP-induced hyperplasia and hypertrophy of these cells. " 01/01/2006 - "Conversely, YM218 potently suppressed [Ca(2+)](i) elevation, activation of MAP kinase and hyperplasia induced by AVP. " 06/01/2007 - "Effect of YM218, a nonpeptide vasopressin V(1A) receptor-selective antagonist, on rat mesangial cell hyperplasia and hypertrophy." 05/24/2006 - "YM218 showed high affinity for vasopressin V(1A) receptors, exhibiting a K(i) value of 0.18 nM. Vasopressin concentration-dependently increased intracellular Ca(2+) levels and induced hyperplasia and hypertrophy in cultured mesangial cells, YM218 potently inhibited these vasopressin-induced responses. "
2.	Hypertrophy 06/01/2007 - "YM218 potently prevented AVP-induced hyperplasia and hypertrophy of these cells. " 06/01/2007 - "Effect of YM218, a nonpeptide vasopressin V(1A) receptor-selective antagonist, on rat mesangial cell hyperplasia and hypertrophy." 05/24/2006 - "YM218 showed high affinity for vasopressin V(1A) receptors, exhibiting a K(i) value of 0.18 nM. Vasopressin concentration-dependently increased intracellular Ca(2+) levels and induced hyperplasia and hypertrophy in cultured mesangial cells, YM218 potently inhibited these vasopressin-induced responses. "
3.	Proteinuria 12/01/2006 - "To this end, the effect of the vasopressin V1a-receptor-selective antagonist, YM218, was studied on proteinuria and focal glomerulosclerosis in early and late intervention after 5/6 nephrectomy in rats, and compared with an angiotensin-converting enzyme inhibitor (ACE-I). "
4.	Focal Segmental Glomerulosclerosis (Glomerulosclerosis, Focal) 12/01/2006 - "To this end, the effect of the vasopressin V1a-receptor-selective antagonist, YM218, was studied on proteinuria and focal glomerulosclerosis in early and late intervention after 5/6 nephrectomy in rats, and compared with an angiotensin-converting enzyme inhibitor (ACE-I). "

Related Drugs and Biologics

1.	Vasopressins (Vasopressin)
2.	Phosphotransferases (Kinase)
3.	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)

Related Therapies and Procedures

1.	Nephrectomy